VEGFA and ovarian cancer: Anti-VEGF therapy using a monoclonal antibody neutralizing VEGF-A was known to cause severe glucose deprivation in subcutaneous xenografts of ovarian cancer, as shown by induced metabolic bioluminescence imaging [12].